The application of pharmacodynamics in the optimization of antibiotic therapy

Formulary

Volumn 38, Issue 5, 2003, Pages 294-319

  Chung, Ellen ^a   Amsden, Guy W ^b   Nafziger, Anne N ^b   Bertino Jr , Joseph S ^b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EXPOSURE; HUMAN; NONHUMAN; PHARMACODYNAMICS; REVIEW; TIME;

EID: 0038218051     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Rolinson GN; Forty years of β-lactam research. J Antimicrob Chemo 1998;41:589-603.
2. Craig WA. Pharmacokinetic/Pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
3. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Internat J Antimicrob Agents 2002;19:355-8.
4. Sanchez-Navarro A, Sanchez Recio MM. Basis of anti-infective therapy: Pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualization. Clin Pharmacokinet 1999;37:289-304.
5. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999;37:1-16.
6. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983;11:233-8.
7. Chiu LM, Amsden GW. Intrapulmonary pharmacokinetics of antibacterial agents: Implications for therapeutics. Am J Respir Med 2002;1:201-9.
8. Cars O. Efficacy of beta-lactam antibiotics: Integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997;27:29-33.
9. Mazzei T, Novelli A, De Lalla F, et al. Tissue penetration and pulmonary disposition of tobramycin. J Chemother 1995;7:363-70.
10. Wright DH, Brown GH, Peterson ML, Rotschefer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-83.
11. Rodvold KA, Piscitelli SC. New oral macrolide and fluoroquinolone antibiotics: An overview of pharmacokinetics, interactions, and safety. Clin Infect Dis 1993;17(Suppl 1):S192-9.
12. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
13. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Internat J Antimicrob Agents 2001;18:S11-5.
14. Mouton JW. Why the AUC/MIC ratio should not be used to predict the effects of β-Lactams. Clin Infect Dis 2002;35:209-10.
15. Craig WA, Ebert S. Kinetics and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1991;74:15-22.
16. Nishida M, Murakawa T, Kaminura T. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels. Antimicrob Agents Chemother 1978;14:6-12.
17. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22.
18. Vogelman B, Gudmundsson S, Leggett JE, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
19. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
20. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations. Antimicrob Agents Chemother 1998;42:2375-9.
21. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-92.
22. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
23. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28-37.
24. Vogelman B, Gudmundsson S,Turnidge J, et al. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157:287-98.
25. Duffull SB, Begg EJ, Chambers T, Barclay ML. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob Agents Chemother 1994;38:2480-2.
26. Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998;42:2739-44.
27. Knudsen JD, Fuursted K, Raber S, et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000;44:1247-54.
28. Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know about antibiotic pharmacodynamics? Pharmacother 2001;21:302S-18S.
29. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.
30. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90.
31. Lacy MK, Lu W, Xu X, et al. Pharmacodynamics comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-7.
32. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999;43:79-86.
33. Lister PD. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: Impact of Area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 2002;46:69-74.
34. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996;40:627-32.
35. Kiem S, Craig WA.Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoroquinolones against Streptococcus pneumoniae [abstract A-492]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, Calif.
36. Bauernfeind A, Jungwirth P, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 1995;23:316-21.
37. Novelli A, Fallani S, Cassetta MI, et al. In vivo pharmacodynamic evaluation of clanthromycin in comparison to erythromycin [abstract 997]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 26-29, 1999; San Francisco, Calif.
38. Craig WA, Kiem S, Andes DR. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin [abstract no 1264]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-30, 2002; San Diego, Calif.
39. Tessier PR, Kim MK, Zhou W, et al. Pharmacodynamics assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002;46:1425-34.
40. Den Hollander JG, Knudsen JD, Mouton JW, et al. Comparison of pharmacodynamics of azithromycin and erthyromycin in vitro and in vivo. Antimicrob Agents Chemother 1998;42:377-82.
41. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamics theories? CID 2001:32(Suppl 1);S39-46.
42. Mouton JW, van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999;43:2473-8.
43. MacGowan A, Rogers C, Bowker K. In vitro models, in vivo models, and pharmacokinetics: What can we learn from in vitro models? Clin Infect Dis 2001;33(Suppl. 3):S214-20.
44. White RL. What in vitro models of infection can and cannot do. Pharmacotherapy 2001;21:292S-301S.
45. MacGowan A, Bowker K. Developments in PK/PD: Optimising efficacy and prevention of resistance, a critical review of PK/PD in in vitro models. Internat J Antimicrob Agents 2002;19:291-8.
46. Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984;77:43-50.
47. Eagle H, Fleischman R, Levy M. "Continuous" vs "Discontinuous" therapy with penicillin, the effect of the interval between injections on therapeutic efficacy. New Engl J Med 1953;248:481-8.
48. Sande MA, Korzeniowski OM, Allegro GM, et al. Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the postantibiotic effect in vivo. Rev Infect Dis 1981;3:98-109.
49. Mouton JW, Vinks AA. Is continuous infusion of β-lactam antibiotics worthwhile? - efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996;38:5-15.
50. Nicolau DP, McNabb J, Lacy MK, et al. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during treatment of nosocomial pneumonia. Clin Drug Invest 1999;18:133-9.
51. Craig WA, Ebert SC. Continuous infusion of βlactam antibiotics. Antimicrob Chemother 1992;36:2577-83.
52. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986;5:319-24.
53. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987:155;93-9.
54. Kashuba ADM, Bertino, Jr. JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms. Antimicrob Agents Chemother 1998;42:842-4.
55. Wallace AW, Jones M, Bertino JS. Evaluation of four once-daily aminoglycosides dosing nomograms. Pharmacotherapy 2002;22:1077-83.
56. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998;279:125-9.
57. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-7.
58. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
59. Gustafsson I, Engstrand L, Cars O. In vitro pharmacodynamic studies of activities of ketolides HMR3647 (Telithromycin) and HMR 3004 against extracellular of intracellular Helicobacter pylori. Antimicrob Agents Chemother 2001;45:352-5.
60. Munckhof WJ, Borlace G, Turnidge JD. Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant Gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004. Antimicrob Agents Chemother 2000;44:1749-53.
61. Andes DR, Craig WA. In vivo pharmacodynamics of ABT-733, a new ketolide antibiotic [abstract 2139]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 17-20, 2000; Toronto, Ontario, Canada.
62. Drusano GL, Preston SL, Leroy B, et al. Pharmacodynamics of telithromycin in the treatment of community-acquired pneumonia [abstract 2186]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, Ill.
63. Minto C, Schnider T. Expanding clinical applications of population pharmacodynamic modeling. Br J Clin Pharmacol 1998;46:321-3.
64. Bonate PL. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 2001;40:15-22.
65. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;38:151-7.
66. Coyle EA, Kaatz GW, Rybak MJ. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:1654-9.
67. Fazilli T, Louie A, Tam V, et al. Effect of inoculum on the pharmacodynamic breakpoint dosage that prevents selection of gatifloxacin resistance in ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae [abstract 445]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec 16-19, 2001; Chicago, Ill.
68. Tam VH, Louie A, Deziel MR, et al. Pharmacodynamics of BMS-284756 and ciprofloxacin against Pseudomonas aeruginosa and Klebsiella pneumoniae in hollow-fiber system [abstract 443]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec 16-19, 2001; Chicago, Ill.
69. Thomas JK, Forrest A, Bhavnanl M, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-7.
70. Shales DM, Gerding DN, John JF, et al. Society for Health Care Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-99.